Clinical Trials Directory

Trials / Completed

CompletedNCT05579574

A Study to Investigate the Interaction of BMS-986322 and a Combined Oral Hormonal Contraceptive (Ethinyl Estradiol [EE]/Norethindrone [NET]) in Healthy Female Participants

An Open-Label, Single-Sequence, Crossover Study to Investigate the Interaction of Multiple Doses of BMS-986322 at Steady State and Multiple Doses of a Combined Oral Hormonal Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female Participants

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
42 (actual)
Sponsor
Bristol-Myers Squibb · Industry
Sex
Female
Age
18 Years – 40 Years
Healthy volunteers
Accepted

Summary

The purpose of this study is to evaluate the effect of multiple doses of BMS-986322 on the pharmacokinetics (PK) of Loestrin components in healthy female participants.

Conditions

Interventions

TypeNameDescription
DRUGBMS-986322Specified dose on specified days
DRUGLoestrinSpecified dose on specified days

Timeline

Start date
2022-10-21
Primary completion
2023-06-01
Completion
2023-06-01
First posted
2022-10-14
Last updated
2023-08-18

Locations

2 sites across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT05579574. Inclusion in this directory is not an endorsement.